CURRENT REPORT 42/2023
October 16, 2023

Posters on preclinical data on PRMT5 and Synthetic Lethality Platform presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company", "Ryvu") announces that today, on October 16, 2023, Ryvu presented the latest data on PRMT5 and its synthetic lethality platform at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference, taking place in Boston, Massachusetts.

Poster presentations concern:

- preclinical data from Ryvu's PRMT5 program in MTAP-Deficient cancers and its synthetic lethality platform in colorectal cancer models, highlighting the potential of Ryvu's synthetic lethality platform based on primary cells
- Ryvu's Partner Menarini Group presented preclinical data on MEN1703 (SEL24) showing anti-tumor activity in B-cell lymphomas, supporting the Phase II clinical program

Details on the poster presentations are as follows:

Abstract Title: "*Discovery of Novel MTA-cooperative PRMT5 Inhibitors as Targeted Therapeutics for MTAP-deleted Cancers*"

- Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors with outstanding drug-like physicochemical properties and the ability to block methyltransferase activity of PRMT5 with nanomolar IC50 values. The novel, optimized inhibitors exhibit a significantly improved PK profile, and in addition, the compounds show antitumor efficacy and target engagement in vivo, providing a strong foundation for further development.

The PRMT5 project's development timeline includes the initiation of IND-enabling studies in 2024.

Abstract Title: "*A Comprehensive Platform for Unraveling the Molecular Mechanisms and Vulnerabilities of Colorectal Cancer: A Step Forward in Target Discovery*"

- Ryvu has pioneered an extensive platform that employs primary colorectal cancer (CRC) models, originated from human intestinal stem cells. This approach enables high-throughput phenotypic assays and CRISPR/Cas9 genomic screenings, surpassing conventional industry standards. The robustness of these models has been confirmed through Ryvu's proprietary ranking algorithm, which identifies potential synthetic lethal drug targets, particularly in KRAS-driven cells.

Abstract Title: "*MEN1703/SEL24, A Potent PIM Inhibitor, Demonstrates Promising Anti-Tumor Activity in Activated B Cell Like DLBCL, Mantle Cell Lymphoma and Marginal Zone Lymphoma Cells*"

- Pharmacological inhibition with MEN1703 (SEL24), a first-in-class, oral, dual type I PIM/FLT3 inhibitor shows anti-proliferative effects in B cell lymphomas of various histotypes. Importantly, MEN1703 was effective in lymphoma cells resistant to other treatments inducing apoptosis in most cell lines. RNA-Seq indicated that the molecule modulates the transcriptome of highly responsive DLBCL cell lines differently from other, poorly responsive cells, providing clues to mechanisms involved in sensitivity to PIM inhibitors and supporting potential in treating B-cell lymphomas.

Posters are available on the Ryvu corporate website: https://ryvu.com/investors-media/publications/.

Ryvu informs that it will host a webinar today, at 9:30 am CEST to discuss the PRMT5 data, which will be available here: https://bit.ly/3RL1YWp

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board